AstraZeneca India, a leading global biopharmaceutical company, has received Dr H R Nanji Memorial OPPI Marketing Excellence Awards 2015 for its drug Brilinta (ticagrelor 90 mg) an innovative treatment solution for Acute Coronary Syndrome (ACS).

AstraZeneca India received this Award in the “Best New Pharma Product launch” category. The Award was handed over by Dr V K Subburaj, Secretary, Department of Pharmaceuticals.

According to company sources, AstraZeneca’s medico-marketing initiatives, based on delivering and pursuing excellence in science, have helped improve the lives of patients suffering from ACS in India.

Currently, Brilinta is one of the leading brands by market share in the oral anti-platelet market and remains committed to continue drive a paradigm shift in the way ACS is managed in India.

AstraZeneca India has also supported the ‘OPPI Woman Scientist Award 2015’ received by Prof Vandana B Patravale from ICT, Mumbai. This award recognizes outstanding women research scientists in the field of human healthcare.

Prof Vandana B Patravale holds expertise in the development of novel, cost effective and robust technologies in the field of nano-drug delivery, nano-diagnostics, vaccines and biomedical devices. Her research in malaria prevention and therapy has seen significant success in terms of one granted patent and ready- for-transfer scalable technologies for effective malaria management in cases of pregnancy, and cerebral malaria.

Dr Bhavesh Kotak, vice president, medical and regulatory affairs, AstraZeneca India said, “ACS causes 28 per cent of all cardiovascular deaths globally and there is a huge unmet medical need in this area. We are pleased to receive this recognition for our efforts in improving the lives of ACS patients in India. Additionally as a science-led organisation, we trust in the potential of ideas and support the efforts of research scientists such as Prof Vandana B Patravale.”